IDEAL Conference Vision
The IDEAL conference 2016 will examine how to create a pathway for the effective scientific evaluation of modern surgical treatments, with a focus on the potential of the IDEAL Framework and Recommendations as an evaluation template.
The effective scientific evaluation of modern surgery and other invasive therapeutic interventions based on technology has become an increasingly important issue because of the lack of a clear pathway and the rate at which new technological innovation has increased. Surgical treatments can often be complex and are challenging to evaluate in a way which provides valid evidence of safety, efficacy and cost-effectiveness. This imposes problems on regulators and purchasers of treatment who need to make evidence-based decisions about them.
A strength of the IDEAL framework is the commitment to long-term studies and the use of registries. This helps address problems that arise during diffusion (IDEAL phases 2b -4) when promising procedures move beyond the initial pioneers and carefully selected patients. It is widely recognised that uptake by a broader surgeon base for wider indications can be associated with higher complication rates, but two other sorts of issues, arising most notably for new devices, have received less attention: (1) Justice and access-to-care issues associated with rolling out new interventions.
(2) The need for scalable models of technical support for innovative devices. This paper explains how and why diffusion processes can influence patterns of access to new procedures and lead to inequities; and provides an account of why technical support protocols must be carefully developed for broad-scale deployment. Notably, once the clinicians and engineers who pioneered the technology can no longer provide follow-up support to increasing numbers of recipients, industry may step in to provide technical support, with implications for outcomes and cost and potential for conflicts of interest. As it stands, the IDEAL framework does not explicitly recognise issues of fair access to care and models for technical support. These issues may appear to be beyond the remit of IDEAL, but this shouldn't be the case: given their implications for both the clinical effectiveness and cost-effectiveness of interventions, these issues should be regarded as critical to robust evaluation. The discussion is informed by experiences with robotic surgery and vascular devices. Guys and St Thomas' NHS Foundation Trust, London, UK, 2 Royal Sussex County Hospital, Brighton, UK, earliest stages (0-1) of the IDEAL framework, using innovative bilateral breast reconstruction as an example.
Methods:Using decision modeling, we quantified expected costs and quality-adjusted life years (QALYs) of the current standard of deep inferior epigastric perforator (DIEP) flap breast reconstruction surgery, compared with an innovation aimed at reducing complications and surgery time. We first explored the maximum impact of eliminating all complications. Second, we modeled three scenarios with varying complication and surgery time reduction. Third, in a threshold analysis we estimated the maximum price of the innovation.
Results:
If the innovation prevents all complications, it adds 0.0079 QALYs and saves €600 per patient. Scenario analysis showed cost savings between €256 and €828 per patient, with QALY gains up to 0.002. If the innovation reduces 50% of complications and 45 minutes of surgery time, it may cost up to €1122 per surgery.
Discussion:
In a field struggling with cost containment, decision modeling can prove key to separating promising innovations from costly failures in an early stage. In this example, decision modeling showed that it seems worthwhile to develop the innovation because it potentially saves money, with a small quality of life gain. The pace of innovation in radiation oncology is high, and the window of opportunity for evaluation narrow. Financial incentives, industry pressure and patients' demand for 'high-tech' treatments have led to widespread implementation of innovations without robust evidence of improved outcomes. Examples include proton therapy and intensity modulated radiotherapy.
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Evaluation of innovation in radiation oncology: R-IDEAL
Like surgery, evaluation of innovations in radiation oncology is complicated by continuous technical development, team and operator dependence, and differences in quality control. Contrary to surgery, radiotherapy innovations may be used in various ways, eg. at different tumor sites and with different aims, including margin reduction, treatment adaptation, and dose escalation. Also, the effect of radiation treatment can be modeled, allowing better prediction of potential benefits and improved patient selection. We adapted the IDEAL framework to fit the radiation oncology setting. Key distinctive features of 'R-IDEAL' include the important role of predicate and modeling studies (stage 0), randomization at an early stage in the development of the technology, and long-term follow up for late toxicity. R-IDEAL is applied in the evaluation of a recent innovation in radiation oncology, the MRI guided linear accelerator (MR-Linac). MR-Linac combines a radiotherapy accelerator with 1.5 Tesla MRI, allowing accurate targeting, dose escalation, and margin reduction, and is expected to lead to an increase in hypofractionated radiation treatments, improved tumor control, higher cure rates and less toxicity. An international consortium, with participants from nine large cancer institutes from Europe and the US, has adopted the R-IDEAL framework to work towards coordinated, evidence-based introduction of the MR-Linac.
Small Simple Trials: A Strategy to Study Rare Surgical Condition.
James Wright
University of Oxford, Oxford, UK
Many surgical conditions are relatively rare making surgical trials logistically difficult. Furthermore many surgeons and surgical centres are relatively inexperienced in the procedures of clinical trials. Large simple trials have enormous sample sizes, broad entry criteria, minimal data collection, and objective end points. Modifying that concept, small simple trials are a strategy to address rare surgical disease. The choice of a small simple trial influences both the study question, as well as trial administration. Study questions for small simple trials must have straightforward and noncontroversial diagnosable conditions, treatments that are easy to proficiently deliver, short-term straightforward and ideally objective outcomes. In addition to minimal data collection, as many aspects of trial management as possible are centralised to address the issue of site trial (in)experience including ethical review, contract management, and arrangements for patient follow up. Small simple trials enrol few patients in many centres (rather than many patients in a few centres) to achieve sample size, but also reduce the burden on centres. This model was used to enrol 90 children with simple bone cysts in 23 centres in less than 2 years to address an important clinical question comparing two intra-lesional treatments. While still prone to baseline prognostic differences and not amenable to all study questions, small simple trials are one strategy to study relatively rare surgical diseases. . The cost-effectiveness is known at 30-day follow-up; realworld 90-day outcomes, however, are unknown. We report 90-day outcomes using a large database serving as a registry.
Methods: A comprehensive all-age, all-payer, statewide database was used to group patients treated emergently for MLBO into 4 management groups: Group1 (stenting); Group2 (stenting and resection within 14days); Group3 (resection with primary anastomosis); and Group4 (stoma creation with/without resection).
Results: 2,435 patients were treated for MLBO from 2009 -2013 Group2=57; Group3=1,388; Group4=755) . Given the small number in Group2, this group was removed from analysis. There were no differences between age, gender, or comorbidity. High-volume centers were more likely to perform stenting compared to low-volume centers (19.4% vs 3.5%;p<0.01). There were no differences in major complication rates during the index hospitalization and 90-days postprocedure. Group1 had the highest rate of 90-day readmissions (42.6% vs 26.9% and 30.3%;p<0.01) and reoperations (17.0% vs. 2.7%, and 4.0%;p<0.01) compared to Group3 and 4. While total median charges were significantly lower for Group1 during the index hospitalization(p<0.01), there was no difference at 90-days(p=0.11).
Conclusion: In this IDEAL Stage 4 study we found that stenting remains an uncommon intervention for patients treated emergently for MLBO. 30-day benefits of stenting are eclipsed at 90-days owing to higher readmission and reoperations rates. New technology development is needed to improve longer-term outcomes of stenting. Testing should be performed using trials nested within registries with longer-term follow-up. Introduction: CELS is an alternative approach to bowel resection for the management of benign colon polyps that fail endoscopic removal. The technology was developed by Cornell surgeons (JM) and has been used by a larger group of investigators. We report a comprehensive analysis of long-term outcomes and costs comparing CELS to traditional surgical options.
3-Year Outcomes and Cost-Savings of Combined Endoscopic Laparoscopic Surgery (CELS) for Benign Colon Polyps
Methods: We performed an IDEAL Stage 2a-2b study to evaluate 3-year outcomes in 102 patients with colon polyps that underwent CELS at a major academic center from 2003-2014. Analysis of outcomes utilized two-sample independent t-test and Fisher's exact test. Preoperative factors that predict risk of conversion to partial bowel resection were determined through multivariate linear/logistic regression modeling. A non-recursive decision tree was designed and interrogated to determine intention to treat (ITT) costing estimates for CELS versus laparoscopic/open resection approaches.
Results: 62% of cases underwent CELS. Complication rates were significantly higher in the conversion to resection group versus the CELS group (28% vs. 2%,p<0.0005). Median LOS for successful CELS was significantly shorter compared to ITT CELS, laparoscopic and open resection (1day vs. 2days vs. 5days vs. 6days,p<0.00005). The perioperative cost savings for ITT CELS compared to laparoscopic and open resection was $4,636 and $10,530, respectively. There was no difference between groups in post-operative colonoscopy requirement.
Conclusions: CELS is at IDEAL Stage 2a-2b and is less morbid and costly than bowel resection for colon polyps that fail endoscopic removal. Widespread use of CELS could result in large cost savings across the population while maintaining clinically equivalent outcomes.
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Stereotactic body radiotherapy followed by surgery for unstable spinal metastases: Technical feasibility and safety study according to the IDEAL stages 1 and 2a. Objective: Standard treatment of unstable vertebral metastases includes stabilizing surgery followed by radiotherapy after an interval of at least two-weeks. This interval is required for adequate wound healing, but delays time to radiotherapy-induced pain relief and local tumor control. Most radiotherapy schemes require multiple hospital visits, and induce inadequate pain relief in 60-70% of patients. Alternative treatment strategies with faster and better pain relief and less hospital visits are needed. Stereotactic body radiotherapy (SBRT) can avoid irradiation of the surgical area to prevent impaired wound healing. This study aims to assess safety and feasibility of single fraction SBRT followed by surgical stabilization within 48-hours for unstable spinal metastases.
Methods: Thirteen patients will be included in this IDEAL stage I/IIa study feasibility and safety study. SBRT is used to deliver 18Gy on the metastasis and 8Gy on the vertebra. Surgical stabilization follows within 48-hours according to routine practice. Information on demographic and clinical characteristics, treatment, toxicity (grade 3-4), complications and survival is systematically collected Results: So far, six consecutive patients have successfully been treated, none of whom experienced wound complications or toxicity. Patients experienced no discomfort during SBRT. No technical modifications were made. Outcomes and Analysis: Propensity score matching used to compare perioperative and survival outcomes, including lymph node yield (LNY), perioperative complications and healthcare costs.
Conclusion
Results: RARC (n=385) increased from 0.7% of radical cystectomies in 2002 to 18.5% in 2012 (p<0.001). RARC was associated with greater LNY with 41.5% vs. 34.9% having ≥10 lymph nodes removed (RR 1.1, 95% CI 1.01-1.22, p=0.03) and shorter mean length of hospitalization at 10.1 (± SD 7.1) days vs. 11.2 (±8.6) days (p=0.004). Inpatient costs were similar, RARC was associated with increased home healthcare utilization (RR 1.14, 95% CI 1.04-1.26, p=0.009) and higher 30 (p<0.01) and 90-day (p<0.01) costs. Median follow-up of 21 months (IQR 6-52), overall survival (HR 0.88, 95% CI 0.74-1.05) and cancer-specific survival (HR 0.91, 95% CI 0.66-1.26) were similar.
Conclusions: RARC provides equivalent perioperative and middle-term outcomes to ORC. As an IDEALS Phase 3 study, this study demonstrates the early and middle-term clinical outcomes and cost effectiveness of the robotic approach. It furthermore highlights the need for additional long-term and randomized studies for continued comparative effectiveness assessment of RARC vs. ORC. Conclusions: RARP associated with better intermediate cancer control, evidenced by less use of additional therapies and better overall survival. An IDEALS Phase 3-4 study, this highlights need for longer-term follow-up to assess differences in cancer specific survival, which was similar during our follow-up. This study provides reassurance regarding the adoption of a more expensive technology in the absence of randomized controlled trials. Material & Methods: Following the IDEAL a unique case of AM-assisted abdominal repair of a complex vesico-vaginal fistula (VVF) in a 64-year women was performed. A preliminary animal study was conducted to show the feasibility of the method. In a total of 26 sprague male rats a small defect at the bladder dome was set and repaired by grafting with a multilayer cryopreserved AM from human caesarian section. Bladder volume capacity and leakage after grafting were measured. Peri-and early postoperative complications were assessed. Histological and immunohistological analyses were performed to look for the degradation of AM, graft rejection and the ingrowth of surrounding tissue 7, 21 and 42 days after the implantation.
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Reconstruction of bladder defects with amniotic membrane -Step 1-2 of IDEAL recommendations of surgical innovation
Results: In the case of VVF-repair a recurrent fistula was detected 8 month after the surgery. In the animal experiment two rats died due to sepsis. All other rats survived, had no severe complications and showed no signs of leakage. The bladder capacity did not change over time. First signs of AM degradation were found 7 days postoperatively and this process was completed between 21 and 42 days. No severe signs of inflammation were detected.
Conclusions: For the first time we applied AM-assisted bladder repair. Further allogenic human cohort and randomised studies are necessary to proof the possible indications.
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Is more evidence always better? The value of adding decision analytical modeling to the IDEAL framework Background: Randomized clinical trials (RCT) are the golden standard to evaluate the effectiveness of surgical interventions. But how much evidence is needed to assess (cost-)effectiveness and is further research warranted? Decision modeling can provide valuable insight in these answers.
To study the merits of decision analytical modeling as compared to another RCT, we analyzed the (cost-)effectiveness of laparoscopic (LDP) versus open distal pancreatectomy (ODP).
Methods:
We modeled the clinical pathway for LPD and ODP in a decision-tree. Estimates and confidence intervals regarding both the effectiveness and costs were based on current literature and expert opinion. We studied whether LPD or ODP appears to be most (cost-)effective, and analyzed at which parameter value the (cost-)effectiveness changes. Furthermore, we performed sensitivity analyses to study the robustness of the results. Results: Our model shows that LDP appears to be cost-effective over ODP under almost all circumstances. Only if the 30day mortality rate is 2.6 times higher in LDP compared to ODP, pneumonia occurs in 41% of LDP cases, incisional hernias occur in 24% which all need surgical repair, 78% needs a conversion, or if LDP patients would have a 5.8 days longer in hospital stay than ODP patients then LDP would be less (cost-)effective. Taking all confidence intervals into account, LDP has a probability of 100% on being (cost-) effective.
Conclusion:
LDP is more cost-effective than ODP and a new trial will probably not change this view. This example shows that decision analytical modeling can further inform the IDEAL framework, and precludes further research waste. 
Departments of Surgery and Intensive Care Medicine, Aberdeen Royal Infirmary, Aberdeen, UK
The IDEAL framework recommends that the evaluation of novel interventions should progress through defined stages, but there is limited guidance on when to progress from observational studies to randomised trials.
This abstract describes our experience of designing a study to evaluate REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta), a complex interventional procedure for exsanguinating haemorrhage caused by traumatic injury.
To date, REBOA has undergone evaluation at IDEAL stages 1, 2a, and 2b, although the 2b evaluation comprised a single, retrospective, propensity score matched study. These studies reported conflicting results, raising some concerns about the safety of the procedure.
Feedback from potential funders, in response to an outline proposal for a prospective observational study (to undertake a more robust 2b evaluation), questioned whether such a design would provide convincing evidence of safety or efficacy, even with case mix adjustment.
A randomised study is the optimal method to provide a truly fair comparison but identifying when there is enough observational data to inform the design of a conventional randomised trial is challenging.
We now propose a combined IDEAL stage 2b/3 study. The design incorporates a feasibility phase, in keeping with a stage 2b study, to gather empirical data prior to progression to a full trial, with a Bayesian group sequential design, in keeping with a stage 3 study.
Our experiences highlight the difficulties of knowing when to progress from observational to randomised evaluations, and that such decisions can be influenced by a number of factors, including the recommendations of potential funders. 
Milton Keynes Hospital, Milton Keynes, UK
Orthotic collars are used to manage cervical spine injuries in the acute pre-hospital setting and as a definitive treatment strategy. Patients must be fitted with an appropriately sized orthosis to ensure adequate cervical immobilisation. This study aims to validate a new iPhone application to objectively quantify range of cervical motion and detect inadequately sized collars. By using the iPhone's inbuilt gyroscope, we can measure motion of the cervical spine in three planesflexion/extension (FE), lateral flexion (LF) and axial rotation (AR). These parameters were measured at baseline movement and with two different cervical collars: 1) Laerdal Stifneck (sizes short, regular, tall) and 2) Aspen Vista (sizes 1, 4, 6). The results of this study show statistically significant variation in cervical spine range of motion between optimally and poorly sized collars. The mean degrees of cervical motion without an orthotic device was 112⁰ (FE), 103⁰ (LF) and 148⁰ (AR). Optimum Laerdal collar selection allowed mean degrees of cervical motion of 42.9⁰ (FE), 45.2⁰ (LF) and 60.2 (AR). Optimum Vista collar selection allowed 48.9⁰ (FE), 65.8⁰ (LF) and 77.4⁰ (AR). An incorrectly sized Laerdal collar allowed 58.0⁰ (FE), 59.1⁰ (LF) and 89.1⁰ (AR) compared to an incorrectly sized Vista collar of 68.9⁰ (FE), 79.4⁰ (LF) and 107.8⁰ (AR). We demonstrate that the iCollar application can objectively quantify cervical motion between different collar types/sizes. This can ensure optimal collar selection so that adequate motion restriction is achieved. This application can also be used to identify poorly fitting and inadequately sized cervical collars.
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The X-Bolt Dynamic Hip Plating System: evaluating a novel surgical device for hip fracture surgery We describe the challenges faced in the assessment of a novel surgical device, the X-Bolt, for the treatment of hip fractures from IDEAL stage 2a to 3. The X-Bolt represents an innovation comapred with the current standard of care device, the Sliding Hip Screw.
Assessment began at Stage with a consecutive series of 25 participants in a single centre with 'enthusiast' surgeons in 2008. Challenges here were around appropriate surgeon training and support, developer and distributor inexperience in the NHS market place and institutional resistance to change.
We conducted a single centre randomised, standard of care controlled feasibility trial. This was a pragmatic study to test feasibility -inclusion criteria were wide, multiple operating surgeons were involved and follow-up mirrored clinical practice. Ethical approval was granted by NRES, who strongly supported the stepwise progression of the research effort. Once institutional friction had dissipated collaboration with the developer led to successful accrual. Stakeholders' concerns were allayed through a demonstrably strong governance framework that supports randomised trials and trials units.
The feasibility study informed Stage 3 -a multicentre randomised trial to assess clinical and cost effectiveness -recruitment is planned to begin in April 2016. The main threat to the delivery of the trial is assessed to be surgeon compliance with recruitment. That same institutional friction is now expected across multiple sites. Strategies to counter this risk include early procurement of the device at centres, the recruitment of centres with a track record in trauma trials and the fostering of PIs.
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Radical cystectomy in epidural anaesthesia -feasibility analysis using the IDEAL recommendations Objective: To describe our experience with radical cystectomy under epidural anaesthesia and to classify this method for the first time according to the IDEAL recommendations for surgical innovations. Material and Methods: Medical records of 3 patients who underwent the procedure were retrospectively evaluated with focus on clinical data, intraoperative and perioperative parameters and postoperative complications. A literature review of recent reports of this technique has been performed and the method has been evaluated using the IDEAL criteria in order to define its current status of evidence. Results: The procedure was performed under epidural anaesthesia in three male patients with a mean age of 73 years (range: 66-79) and ASA Score of II (n=1) and III (n=2). Surgical time ranged from 159 to 261 min. Mean intraoperative blood loss was 1000 ml (700-1300 ml) requiring no perioperative transfusions. All patients stayed one day at Intensive Care Unit, mean overall hospital stay was 19 days. Only minor complications were documented. The current report according to IDEAL corresponds to stage 1 whereas the entire method provides a case series ranking the procedure at stage 2a. Conclusions: In this study we confirm functional results of the previously described technique as a feasible and applicable method for selected indications. The highest level for the method reaches 2a (D) according to IDEAL. The PUR CLINIC, Clermont, USA Objectives: Microsurgical vasovasostomy (VV) failures have been attributed to granuloma/scar formation at the anastomosis site. A previous rodent study has shown that using a bio-wrap to cover the VV site reduces granuloma/scar formation. We report the early stage investigation of a novel biowrap assisted modified single layer robotic microsurgical vasovasostomy (RMV) technique.
Materials & Methods:
We obtained IRB approval for four RMV patient cases and performed a modified single layer vasal anastomosis utilizing five double arm 10-0 nylon sutures in all cases. The bio-inert matrix material (Axogen Inc., Alachua, FL) was placed around the anastomosis site and anchored using two 9-0 nylon sutures to the muscularis of the vas deferens. Preoperative and postoperative pain was assessed using an externally validated pain QOL impact score (PIQ-6). Semen analyses were obtained at the second and fifth months postop.
Results: Three bilateral RMV and 1 crossover unilateral RMV procedures were performed (12/2012-3/2013) . Median duration from vasectomy was 4.5 years (1-9). Median follow up was 8 months. Patency (> 1 million motile sperm per ejaculate) was achieved in all 3 bilateral RMV patients. All four patients had a significant reduction in pain (78, 78, 69, 68 to 57, 52, 44, 54 , respectively at 6 month follow up).
Conclusion:
Based on an IDEAL Stage 1 study, bio-wrap assisted modified single layer robotic microsurgical vasovasostomy is safe, feasible and has promising preliminary outcomes with regards to semen parameters meriting further investigation. 
University of Stirling, Stirling, UK,
The GASTROS study (GAstric cancer Surgery Trials Reported Outcome Standardisation) is an international initiative which aims to develop a core outcome set (COS) -a minimum standardised group of outcomes -which should be reported by all future gastric cancer surgery trials. This will enable more accurate comparison of outcomes from different surgical approaches. GASTROS is fully funded by the National Institute for Health Research and supported by the Medical Research Council's Hubs for Trials Methodology Research. Here we present our study protocol.
Methods: GASTROS has 3 stages. Stage 1 involves undertaking a systematic review of studies to identify a 'long-list' of possible outcomes to include in the COS. Qualitative interviews with gastric cancer patients will be undertaken to identify any further outcomes which patients deem important. Stage 2 involves 3 rounds of a Delphi survey of key stakeholders (surgeons, cancer nurse specialists and patients) to determine which outcomes to include in the COS. Stage 3 will focus on identifying the most appropriate methods of measuring these outcomes.
Anticipated Benefit: This study will enable more reliable comparison of surgical interventions for gastric cancer. It will inform future gastric cancer surgical trials by identifying standardised outcomes relevant to both patients and clinicians. Methods: A systematic review of the 198 journals within the Journal Citation Report 2014 (surgery category) published by Thomson Reuters was undertaken. The online guide for authors for each journal was screened by two independent groups and results compared. Data regarding the presence and strength of recommendation to use reporting guidelines was extracted.
Results: 193 journals were included (following exclusion of duplicate journal names). These had a median impact factor of 1.526 (range 0.047 to 8.327), with 34,036 articles published in total over the two-year window 2012-2013. 62% of surgical journals made no mention of reporting guidelines within their guidance for authors. Of the 38% that did mention them, only 14% required the use of all relevant reporting guidelines. The most frequently mentioned reporting guideline was CONSORT (46 journals).
Conclusion:
The mention of reporting guidelines within the guide for authors of surgical journals needs improvement. Journals should uniformly endorse relevant reporting guidelines and update their instruction to authors to reflect this. This will likely improve methodology and quality of reporting, raising the level of scholarly discourse between authors and the scientific community and reducing frustration amongst readers. , Dennis Orgill Introduction and hypothesis: Most aspects of implants for reconstruction of the pelvic floor are still under debate or poorly studied. Different tools and definitions of success make the comparability of studies and meta-analyses in this field of surgery difficult. The aim of the present study was to prove the feasibility of a register to analyse the outcome after implant application.
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Compliance of Systematic Reviews in Plastic Surgery
Methods:
The available literature on the application of implants for pelvic organ prolapse (POP) and female and male stress urinary incontinence (SUI) repair was reviewed according to IDEAL stages of surgical innovation. A working group was formed to create an online platform for registration and outcome measurement of implant-assisted operations for POP and SUI repair. To date, 20 patients from a previous published study on modified mesh materials were evaluated over 23 months follow up in the register. For validation a previously published modified "satisfaction, anatomy, continence, safety -S.(A.)C.S score" was used.
